Fongit Seed Invest
VC Fund
Plan-les-ouates, Switzerland
Fongit Seed Invest is a VC fund in Plan-les-ouates focused on Health Care and Medical. Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Fongit Seed Invest invests in
Stages Fongit Seed Invest invests in
Countries Fongit Seed Invest invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$1.4M
- Series A
- $2.3M–$3.3M
Investment Focus
Industry
- Health Care 6 (67%)
- Medical 4 (44%)
- Biotechnology 3 (33%)
- Medical Device 3 (33%)
- Life Science 2 (22%)
Stage
- Seed 4 (44%)
- Series A 4 (44%)
- Series B 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gian-Luigi Berini
Chairman
|
Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. | $1M / Seed / Apr 09, 2020 | ||
| EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients. | $1.4M / Seed / Aug 21, 2019 | ||
| B2B SaaS offering AI assistants and shared inboxes for Gmail. | Seed / May 02, 2019 | ||
| Hylomorph is a MedTech company that specializes in providing fibrotic encapsulation solutions in implantable medical devices. The company was founded in 2014 and is headquartered in Zurich, Switzerland. | $3.3M / Series A / Sep 14, 2018 | ||
| Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland. | $2.4M / Series A / Jan 30, 2015 | ||
| Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from: | $2.3M / Series A / Apr 26, 2012 | ||
| Viroblock is a Swiss based company focused on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suited for air filtration products. In fact, previous work has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in standardizedaerobiology experiments. | Series B / Feb 05, 2010 | ||
| Viroblock is a Swiss based company focused on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suited for air filtration products. In fact, previous work has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in standardizedaerobiology experiments. | Series A / Jul 20, 2007 | ||
| Augurix was born out of the real-life experiences of living with Celiac Disease. In 2004, Cecile – a pediatrician with an MD and PhD in immunology – noticed her 18-month old son Simon exhibiting symptoms of the disease. As a professional and having been diagnosed herself some thirty years earlier, she was able to spot the early warning signs. ButCecile was also acutely aware that despite affecting almost 1 in 100 people, Celiac Disease was difficult to diagnose.Cecile and her husband Thierry became determined to find a way to change this, giving parents and their children the best chance of an accurate diagnosis and the ability to live their lives free of the often debilitating symptoms. Using Swiss medical expertise Augurix was founded in 2007, with a mission to provide primary care doctors with an easy-to-use, affordable tool, to lower the hurdle of diagnostics.In 2010 Simtomax® was launched – a rapid screening test for the early determination of Celiac Disease at the point-of-care – finally bringing Cecile’s vision to life. Today, Augurix is pursuing its vision by enlarging its diagnostics offer to other gastrointestinal diseases. | Seed / Oct 20, 2006 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Fongit Seed Invest invest in?
Fongit Seed Invest invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Fongit Seed Invest invest in?
Fongit Seed Invest typically joins rounds of $1M–$1.4M at Seed and $2.3M–$3.3M at Series A. These are whole funding-round sizes, not Fongit Seed Invest's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Fongit Seed Invest took part in.
How do I contact Fongit Seed Invest?
Public channels for Fongit Seed Invest include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fongit Seed Invest?
The team at Fongit Seed Invest includes Gian-Luigi Berini (Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
